Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The group will offer free access to omic and clinical data from the project and develop software to help clinicians use the models in patient care.
The partners have planned a three-year pilot and selected three NCI projects to benefit from supercomputers and expertise offered by four DOE labs.
Myriad Genetics, Kinaxo Biotechnologies, Bavarian Research Foundation, European Commission, Decode Genetics, Ontario Institute for Cancer Research
The $3.8 million program will back assay development, screening tools, toxicity, and elucidation of 3D structures in search of HIV treatments
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.